Aspire Biopharma Files S-1 for Securities Registration

Ticker: ASBPW · Form: S-1 · Filed: Apr 9, 2025 · CIK: 1847345

Sentiment: neutral

Topics: sec-filing, s-1, registration

TL;DR

Aspire Biopharma (fka PowerUp Acquisition) filed S-1, get ready for new shares.

AI Summary

Aspire Biopharma Holdings, Inc. filed an S-1 form on April 9, 2025, to register securities. The company, previously known as PowerUp Acquisition Corp., is incorporated in E9 and has a fiscal year end of December 31. Its business address is located at 194 Candelaro Drive, #233, Humacao, PR 00791.

Why It Matters

This S-1 filing indicates Aspire Biopharma Holdings, Inc. is preparing to offer securities to the public, which could impact its capital structure and future growth prospects.

Risk Assessment

Risk Level: medium — S-1 filings are standard for IPOs or secondary offerings, but the specific details of Aspire Biopharma's business and financial health are not yet fully disclosed in this initial filing.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1 filing for Aspire Biopharma Holdings, Inc.?

The S-1 filing is a registration statement filed with the SEC to register securities for public offering.

What was Aspire Biopharma Holdings, Inc. previously known as?

Aspire Biopharma Holdings, Inc. was formerly known as PowerUp Acquisition Corp.

When was the name change from PowerUp Acquisition Corp. to Aspire Biopharma Holdings, Inc.?

The filing indicates a date of name change as 20210222, suggesting the change occurred on February 22, 2021.

Where is Aspire Biopharma Holdings, Inc. located?

The company's business and mailing address is 194 Candelaro Drive, #233, Humacao, PR 00791.

What is the SIC code for Aspire Biopharma Holdings, Inc.?

The Standard Industrial Classification (SIC) code for Aspire Biopharma Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form S-1 (Form S-1) was filed with the SEC on April 9, 2025 regarding Aspire Biopharma Holdings, Inc. (ASBPW).

View full filing on EDGAR

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing